Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment

Sponsor
Memorial Sloan Kettering Cancer Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02836093
Collaborator
(none)
45
7
84
6.4
0.1

Study Details

Study Description

Brief Summary

Many patients receiving radiation therapy for breast cancer experience fatigue although doctors do not fully understand why. The purpose of this study is to test if patients who experience fatigue during radiation treatment for breast cancer have changes in their capability to perform exercise on a treadmill.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: FACIT-Fatigue 52-point questionnaire

Study Design

Study Type:
Observational
Actual Enrollment :
45 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pilot Study for Assessment of Exercise Capacity in Breast Cancer Patients With Radiotherapy-Related Fatigue
Actual Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
evaluations/assessments

Behavioral: FACIT-Fatigue 52-point questionnaire

Outcome Measures

Primary Outcome Measures

  1. fatigue measurement using the 13-item FACIT-fatigue scale [1 year]

    Fatigue will be assessed using the 13-item FACIT-fatigue scale for the assessment of fatigue in cancer patients.24 The FACIT-Fatigue is a validated questionnaire that was originally developed for the precise evaluation of fatigue levels in cancer patients with anemia. It consists of 13 questions using a 5 point scale (0=not at all; 1 = a little bit, 2 = somewhat, 3 = quite a bit and 4 = very much). It has been used frequently in the clinical trial setting (please see appendix 1). Responses to each question are added with equal weight to obtain a total score. The range of possible scores is 0-52, with 0 corresponding to the highest level of fatigue and 52 corresponding to the lowest level of fatigue.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female

  • ECOG performance status 0 or 1

  • Medical clearance from attending radiation oncologist or medical oncologist to undergo a symptom-limited CPET

  • Currently undergoing intact breast radiotherapy for early stage breast cancer (including TisN0, T1N0, T2N0) or has completed intact breast RT in the last 3 months.

  • Receiving or received a prescribed dose of 4240 cGy in 16 fractions to the whole breast without treatment directed at nodal basins. Patients may also be receiving or have received a boost to the lumpectomy bed at the discretion of the treating physician.

  • Subjects may be treated in the supine or prone position at the discretion of the treating physician.

  • Subjects may be treated with or without a deep inspiratory breath hold technique at the discretion of the treating physician.

  • Identified by the treating radiation oncologist as having significant treatment-related fatigue or minimal treatment-related fatigue and not simply baseline fatigue. A score of "0" on the RTOG fatigue scale will be considered minimal fatigue, while a score of "2" or greater will be considered significant fatigue (moderate fatigue causing difficulty performing some ADLs).

Exclusion Criteria:
  • Currently undergoing post-mastectomy radiation

  • Has received chemotherapy previously or has a plan to receive chemotherapy during the timeframe of study assessment.

  • Any of the following absolute contraindications to CPET, as per American Thoracic Society (ATS) recommendations

  • Acute myocardial infarction (within 3-5 days of any planned study procedures)

  • Unstable angina

  • Uncontrolled arrhythmia causing symptoms or hemodynamic compromise

  • Recurrent syncope

  • Active endocarditis

  • Acute myocarditis or pericarditis

  • Symptomatic severe aortic stenosis

  • Uncontrolled heart failure

  • Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures

  • Thrombosis of lower extremities

  • Suspected dissecting aneurysm

  • Uncontrolled asthma

  • Pulmonary edema

  • Room air desaturation at rest ≤ 85%

  • Respiratory failure

  • Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)

  • Mental impairment leading to inability to cooperate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Memoral Sloan Kettering Basking Ridge (Consent only) Basking Ridge New Jersey United States 07920
2 Memorial Sloan Kettering Monmouth (Consent only) Middletown New Jersey United States 07748
3 Memorial Sloan Kettering Bergen (Consent only) Montvale New Jersey United States 07645
4 Memorial Sloan Kettering Commack (Consent only) Commack New York United States 11725
5 Memorial Sloan Kettering Westchester (Consent only) Harrison New York United States 10604
6 Memorial Sloan Kettering Cancer Center New York New York United States 10065
7 Memorial Sloan Kettering Rockville Centre (Consent only) Rockville Centre New York United States 11570

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center

Investigators

  • Principal Investigator: Beryl McCormick, MD, Memorial Sloan Kettering Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02836093
Other Study ID Numbers:
  • 16-941
First Posted:
Jul 18, 2016
Last Update Posted:
Feb 1, 2022
Last Verified:
Jan 1, 2022
Keywords provided by Memorial Sloan Kettering Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2022